Literature DB >> 16227782

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.

Kirsten L White1, Nicolas A Margot, John K Ly, James M Chen, Adrian S Ray, Martina Pavelko, Ruth Wang, Martin McDermott, S Swaminathan, Michael D Miller.   

Abstract

OBJECTIVE: To determine the mechanisms of resistance of K65R mutant reverse transcriptase (RT) to the currently approved nucleoside and nucleotide RT inhibitors (NRTI).
METHODS: Susceptibilities of K65R mutant HIV-1 to NRTI were determined in cell culture. The Ki/Km values were measured to determine the relative binding or incorporation of the NRTI, and ATP-mediated excision of incorporated NRTI was measured to determine NRTI stability as chain terminators.
RESULTS: K65R HIV-1 had decreased susceptibility to most NRTI, but increased susceptibility to zidovudine (ZDV). Ki/Km values were increased 2- to 13-fold for K65R compared to wild-type RT for all NRTI, indicating decreased binding or incorporation. However, K65R also showed decreased excision of all NRTI compared to wild-type, indicating greater stability once incorporated. At physiological nucleotide concentrations, excision of ZDV, carbovir (the active metabolite of abacavir; ABC), stavudine (d4T), and tenofovir was further decreased, while excision of didanosine (ddI), zalcitabine (ddC), lamivudine (3TC), and emtricitabine (FTC) was unchanged. The decreased binding or incorporation of ZDV by K65R appeared counteracted by decreased excision resulting in overall increased susceptibility to ZDV in cell culture. For ABC, tenofovir, and d4T, despite having decreased excision, decreased binding or incorporation resulted in reduced susceptibilities to K65R. For ddI, ddC, 3TC, and FTC, decreased binding or incorporation by K65R appeared responsible for the decreased susceptibilities in cell culture.
CONCLUSIONS: NRTI resistance in cells can consist of both altered binding or incorporation and altered excision of the NRTI. For K65R, the combination of these opposing mechanisms results in decreased susceptibility to most NRTI but increased susceptibility to ZDV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227782     DOI: 10.1097/01.aids.0000189851.21441.f1

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  26 in total

1.  Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Peter K Quashie; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

2.  Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Robert A Smith; Donovan J Anderson; Bradley D Preston
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.

Authors:  William E Delaney; Adrian S Ray; Huiling Yang; Xiaoping Qi; Shelly Xiong; Yuao Zhu; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Authors:  Michael E Abram; Manuel Tsiang; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

6.  Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Daniel Rajotte; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

7.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

8.  Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).

Authors:  Claudia Reinheimer; Anna Wesner; Oliver T Keppler; Hans Wilhelm Doerr; Eva Herrmann; Martin Stürmer; Christoph Stephan
Journal:  Med Microbiol Immunol       Date:  2016-01-08       Impact factor: 3.402

9.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602

10.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.